Union européenne - français - EMA (European Medicines Agency)

amgen europe b.v. - carfilzomib - le myélome multiple - agents antinéoplasiques - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Canada - français - Health Canada

amgen canada inc - carfilzomib - poudre pour solution - 60mg - carfilzomib 60mg - antineoplastic agents

Canada - français - Health Canada

amgen canada inc - carfilzomib - poudre pour solution - 10mg - carfilzomib 10mg - antineoplastic agents

Canada - français - Health Canada

amgen canada inc - carfilzomib - poudre pour solution - 30mg - carfilzomib 30mg - antineoplastic agents

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - carfilzomibum - poudre pour solution pour perfusion - praeparatio cryodesiccata: carfilzomibum 60 mg, sulfobutylbetadexum natricum 3000 mg, acidum citricum, natrii hydroxidum ad ph, nitrogenium, pro vitro corresp. natrium 216 mg. - onkologikum - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - carfilzomibum - poudre pour solution pour perfusion - praeparatio cryodesiccata: carfilzomibum 10 mg, sulfobutylbetadexum natricum 500 mg, acidum citricum, natrii hydroxidum ad ph, nitrogenium, pro vitro corresp. natrium 37 mg. - onkologikum - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - carfilzomibum - poudre pour solution pour perfusion - praeparatio cryodesiccata: carfilzomibum 30 mg, sulfobutylbetadexum natricum 1500 mg, acidum citricum, natrii hydroxidum ad ph, nitrogenium, pro vitro corresp. natrium 109 mg. - onkologikum - synthetika

Union européenne - français - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - le myélome multiple - agents antinéoplasiques - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Canada - français - Health Canada

janssen inc - daratumumab - solution - 100mg - daratumumab 100mg - antineoplastic agents

Canada - français - Health Canada

sanofi-aventis canada inc - isatuximab - solution - 100mg - isatuximab 100mg - antineoplastic agents